The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Jorveza budesonide OrphanAccelerated assessment | Dr. Falk Pharma GmbH | Esophageal Diseases | 🇪🇺 EU 2018-01-08 | Order → |
| Ocrevus ocrelizumab | Roche Registration GmbH | Multiple Sclerosis | 🇪🇺 EU 2018-01-08 | Order → |
| Prevymis letermovir Orphan | Merck Sharp & Dohme B.V. | Cytomegalovirus Infections | 🇪🇺 EU 2018-01-08 | Order → |
| Tacforius tacrolimus Generic | Teva B.V. | Liver Transplantation; Kidney Transplantation | 🇪🇺 EU 2017-12-08 | Order → |
| Zejula niraparib Orphan | GlaxoSmithKline Trading Services Limited | Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms | 🇪🇺 EU 2017-11-16 | Order → |
| Elebrato Ellipta fluticasone furoate;umeclidinium;vilanterol | GlaxoSmithKline Trading Services Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2017-11-15 | Order → |
| Imatinib Teva B.V. imatinib Generic | Teva B.V. | Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 🇪🇺 EU 2017-11-15 | Order → |
| Ontruzant trastuzumab Biosimilar | Samsung Bioepis NL B.V. | Stomach Neoplasms; Breast Neoplasms | 🇪🇺 EU 2017-11-15 | Order → |
| Trelegy Ellipta fluticasone furoate;umeclidinium;vilanterol | GlaxoSmithKline Trading Services Limited | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2017-11-15 | Order → |
| Cyltezo adalimumab BiosimilarAdditional monitoring | Boehringer Ingelheim International GmbH | Hidradenitis Suppurativa; Arthritis, Psoriatic; Psoriasis; Crohn Disease; Arthritis, Juvenile Rheumatoid; Uveitis; Arthritis, Rheumatoid; Colitis, Ulcerative; S | 🇪🇺 EU 2017-11-10 | Order → |
| Tookad padeliporfin Additional monitoring | STEBA Biotech S.A | Prostatic Neoplasms | 🇪🇺 EU 2017-11-10 | Order → |
| Tremfya guselkumab | Janssen-Cilag International NV | Psoriasis; Crohn Disease; Colitis, Ulcerative | 🇪🇺 EU 2017-11-10 | Order → |
| VeraSeal human fibrinogen;human thrombin | Instituto Grifols, S.A. | Hemostasis, Surgical | 🇪🇺 EU 2017-11-10 | Order → |
| Zubsolv buprenorphine;naloxone | Accord Healthcare S.L.U. | Opioid-Related Disorders | 🇪🇺 EU 2017-11-10 | Order → |
| Miglustat Gen.Orph miglustat Generic | Gen.Orph | Gaucher Disease | 🇪🇺 EU 2017-11-09 | Order → |
| Nyxoid naloxone | Mundipharma Corporation (Ireland) Limited | Opiate Overdose | 🇪🇺 EU 2017-11-09 | Order → |
| Ritonavir Viatris (previously Ritonavir Mylan) ritonavir Generic | Viatris Limited | HIV Infections | 🇪🇺 EU 2017-11-09 | Order → |
| Veanibek (previously Miglustat Gen.Orph) miglustat Generic | Gen.Orph | Gaucher Disease | 🇪🇺 EU 2017-11-09 | Order → |
| Dupixent dupilumab | Sanofi Winthrop Industrie | Dermatitis, Atopic; Prurigo; Esophageal Diseases; Asthma; Sinusitis | 🇪🇺 EU 2017-09-26 | Order → |
| Lutathera lutetium (177Lu) oxodotreotide Orphan | Novartis Europharm Limited | Neuroendocrine Tumors | 🇪🇺 EU 2017-09-26 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.